Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021270014/en/

Media Contact
Caren Scannell
Director, Communications
[email protected]

Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
[email protected]

Source: Vir Biotechnology, Inc.

You May Also Be Interested In

• AI-powered cyber threats light a fire under cybersecurity stocks
• Accenture shares fall on insider sales and analyst downgrade
• Nokia shares recover after analysts call selloff overdone